The 'Dispatched' Week in Review Podcast - 4 October

This is a preview of subscriber content

Subscribe now to continue reading.

A significant structural change in the PBS, which the Government attempted to blunt with 60-day dispensed quantities, is arguably the main growth driver in spending on the program. We discuss the change, which along with others, represents a major reversal in a decades-long approach to medicines access. …

Subscribe now to continue reading.

The 'Dispatched' Week in Review Podcast - 4 October

This is a preview of subscriber content

Latest Video

Most Read

The lesson to learn from the Guild is that you cannot defeat what you do not know

Lilly announces Phase 3 results for triple agonist in obesity and knee osteoarthritis

Algorae unveils major breakthrough in AI-driven drug combination discovery

GBMA to host inaugural summit aimed at addressing medicine shortages

The industry is probably right to resist, it just needs to prepare for the response

New Stories

The industry is probably right to resist, it just needs to prepare for the response

Cynata completes patient enrolment in Phase 2 trial for aGvHD therapy

Prescient secures European approval to launch PTX-100 trial for rare lymphoma

Orthocell lodges European and UK regulatory application for Remplir

Neuren wins second FDA approval for trofinetide with launch of formulation

Dimerix completes adult recruitment in Phase 3 trial for FSGS treatment DMX-200

Radiopharm Theranostics reports high success rate in Phase 2b imaging trial

Sign In

The 'Dispatched' Week in Review Podcast - 4 October

This is a preview of subscriber content

Latest Video

Most Read

The lesson to learn from the Guild is that you cannot defeat what you do not know

Lilly announces Phase 3 results for triple agonist in obesity and knee osteoarthritis

Algorae unveils major breakthrough in AI-driven drug combination discovery

GBMA to host inaugural summit aimed at addressing medicine shortages

The industry is probably right to resist, it just needs to prepare for the response

Follow Us

New Stories

The industry is probably right to resist, it just needs to prepare for the response

Cynata completes patient enrolment in Phase 2 trial for aGvHD therapy

Prescient secures European approval to launch PTX-100 trial for rare lymphoma

Orthocell lodges European and UK regulatory application for Remplir

Neuren wins second FDA approval for trofinetide with launch of formulation

Dimerix completes adult recruitment in Phase 3 trial for FSGS treatment DMX-200

Radiopharm Theranostics reports high success rate in Phase 2b imaging trial